Elaprase Shire plc - Treatment for Hunter Syndrome
Elaprase is a purified form of the human lysosomal enzyme iduronate-2-sulfatase produced by recombinant DNA technology. Elaprase is indicated for the treatment of Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II).Posted: July 2006
Related articles
- Shire Provides Update on U.S. Marketing Application of Elaprase - May 17, 2006
- Shire Files Elaprase (idursulfase) With the FDA for the Treatment of Hunter Syndrome - November 24, 2005
Elaprase (idursulfase) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
